Stockholder's Equity | Stockholder's Equity (a) Stock Equity and Incentive Plan The Company recognizes stock-based compensation in accordance with the provisions of ASC Topic 718, Compensation-Stock Compensation . Stock-based compensation expense was $384 and $558, excluding $1 and $1 of compensation charges related to our Amended and Restated 1996 Employee Stock Purchase Plan, or the ESPP, for the three months ended September 30, 2024 and 2023, respectively, and $1,622 and $1,408, excluding $7 and $25 of compensation shares related to the ESPP, for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, there was $1,428 of total unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.61 years. As of September 30, 2024, there was $2,002 of total unrecognized compensation expense related to restricted stock awards, which is expected to be recognized over a weighted-average period of 2.22 years. Stock Options During the three months ended September 30, 2024, the company issued no shares of common stock upon the exercise of stock options. No shares were surrendered to the Company to satisfy minimum tax withholding obligations. Additionally, during the three months ended September 30, 2024, no stock options were granted and 230 stock options expired, were canceled or were forfeited. During the nine months ended September 30, 2024, the Company issued no shares of common stock upon the exercise of stock options. No shares were surrendered to the Company to satisfy minimum tax withholding obligations. Additionally, during the nine months ended September 30, 2024, 266 stock options were granted and 501 stock options expired, were canceled or were forfeited. During the nine months ended September 30, 2023, 317 stock options were granted and 564 stock options expired, were canceled or were forfeited. The Company has historically estimated the fair value of each option grant on the date of grant using the Black-Scholes option-pricing model. The weighted average assumptions utilized to determine the fair value of options granted during the nine months ended September 30, 2024 and 2023 are as follows: Nine Months Ended September 30, 2024 2023 Risk-free interest rate 4.36 % 4.49 % Expected volatility 48.63 % 43.93 % Expected life (in years) 4.32 4.30 Dividend yield 0 % 0 % As of September 30, 2024, there were 995 options outstanding with a weighted average exercise price of $8.23 per share and 410 options exercisable with a weighted average exercise price of $9.32 per share. Restricted Stock During the three months ended September 30, 2024, 85 shares of restricted stock were granted with a weighted average grant date fair value of $4.51 per share, and no shares of restricted stock were forfeited. Additionally, during the three months ended September 30, 2024, 16 shares of restricted stock vested. During the nine months ended September 30, 2024, 207 shares of restricted stock were granted with a weighted average grant date fair value of $4.82 per share, and 43 shares of restricted stock were forfeited. Additionally, during the nine months ended September 30, 2024, 158 shares of restricted stock vested. As of September 30, 2024, the Company had no unvested outstanding options and no outstanding shares of restricted stock that were subject to performance-based or market-based vesting conditions. (b) Employee Stock Purchase Plan The Company's ESPP affords eligible employees the right to purchase common stock, via payroll deductions, through various offering periods at a purchase price equal to 85% of the fair market value of the common stock on the first or last day of the offering period, whichever is lower. During the three months ended September 30, 2024 and 2023, 0 and 17 shares were issued under the ESPP plan, respectively. During the nine months ended September 30, 2024 and 2023, 24 and 17 shares were issued under the ESPP plan, respectively. The Company recorded compensation charges related to the ESPP of $1 for both the three months ended September 30, 2024 and 2023, and $7 and $25 for the nine months ended September 30, 2024 and 2023, respectively. (c) Stock-Based Compensation Expense The following table presents stock-based compensation expense, including expense for the ESPP, in the Company's consolidated statements of operations for the nine months ended September 30, 2024 and 2023, respectively: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Cost of service sales 8 6 $ 22 $ 15 Cost of product sales $ 5 $ 9 19 25 Research and development 63 162 326 399 Sales, marketing and support 74 63 219 160 General and administrative 235 319 1,043 834 $ 385 $ 559 $ 1,629 $ 1,433 (d) Accumulated Other Comprehensive Loss (AOCL) Comprehensive loss includes net loss, unrealized gains and losses from foreign currency translation, and unrealized gains and losses on available for sale marketable securities. The components of the Company’s comprehensive loss and the effect on earnings for the periods presented are detailed in the accompanying consolidated statements of comprehensive loss. The balances for the three months ended September 30, 2024 and 2023 are as follows: Foreign Currency Translation Total Accumulated Other Comprehensive Loss Balance, June 30, 2024 $ (3,991) $ (3,991) Other comprehensive income 134 134 Net other comprehensive income 134 134 Balance, September 30, 2024 $ (3,857) $ (3,857) Foreign Currency Translation Total Accumulated Other Comprehensive Loss Balance, June 30, 2023 $ (3,955) $ (3,955) Other comprehensive loss (267) (267) Net other comprehensive loss (267) (267) Balance, September 30, 2023 $ (4,222) $ (4,222) The balances for the nine months ended September 30, 2024 and 2023 are as follows: Foreign Currency Translation Unrealized Gain (Loss) on Available for Sale Marketable Securities Total Accumulated Other Comprehensive Loss Balance, December 31, 2023 $ (4,185) $ — $ (4,185) Other comprehensive income 328 — 328 Net other comprehensive income 328 — 328 Balance, September 30, 2024 $ (3,857) $ — $ (3,857) Foreign Currency Translation Unrealized (Loss) Gain on Available for Sale Marketable Securities Total Accumulated Other Comprehensive Loss Balance, December 31, 2022 $ (4,098) $ (12) $ (4,110) Other comprehensive (loss) income (124) 12 (112) Net other comprehensive (loss) income (124) 12 (112) Balance, September 30, 2023 $ (4,222) $ — $ (4,222) |